

### PERSONAL INFORMATION **Raul J. Andrade**

#### WORK EXPERIENCE

---

- January 1982-January 1992 **ASSISTANT PROFESSOR**  
University of Malaga (Spain)  
Department of Medicine.  
University of Málaga. School of Medicine
- January 1992- Present **ASSOCIATE PROFESSOR**  
University of Malaga (Spain)  
Department of Medicine.  
University of Málaga. School of Medicine
- June 2008- Present **FULL PROFESSOR**  
University of Malaga (Spain)  
Department of Medicine.  
University of Málaga. School of Medicine
- January 1988-January 2010 **CONSULTANT PHYSICIAN IN HEPATOLOGY**  
University Hospital of Málaga (Spain)  
Service of Gastroenterology  
University Hospital of Málaga
- January 2010- Present **DIRECTOR Service of Gastroenterology and Hepatology**  
University Hospital of Málaga (Spain)  
**DIRECTOR**  
Service of Gastroenterology and Hepatology  
University Hospital of Málaga

#### EDUCATION AND TRAINING

---

- 1979- **M.D. degree with full honours cum Laude.**  
University of Málaga. (Spain)  
School of Medicine
- 1983- **Certificate (specialist) in Internal Medicine.**  
University of Málaga. School of Medicine (Spain)  
Internal Medicine
- 1987- **Certificate (specialist) in Gastroenterology**  
University of Málaga. School of Medicine (Spain)  
Gastroenterology
- 1988- **Doctor in Medicine. Outstanding cum Laude.**  
University of Málaga. School of Medicine (Spain)  
Medicine

#### ADDITIONAL INFORMATION

---

**Expertise** Hepatotoxicity; Chronic viral hepatitis; Non alcoholic fatty liver disease

**Publications** MOST RELEVANT PUBLICATIONS:

1. CAMILLA STEPHENS, MERCEDES ROBLES-DIAZ, INMACULADA MEDINA-CALIZ, MIREN GARCIA-CORTES, AIDA ORTEGA-ALONSO, JUDITH SANABRIA-CABRERA, ANDRES GONZALEZ-JIMENEZ, ISMAEL ALVAREZ-ALVAREZ, MAHMOUD SLIM, MIGUEL JIMENEZ-PEREZ, ROCIO GONZALEZ-GRANDE, M CARMEN FERNANDEZ, MARTA CASADO, GERMAN SORIANO, EVA ROMAN, HACIBE HALLAL, MANUEL ROMERO-GOMEZ, AGUSTIN CASTIELLA, ISABEL CONDE, MARTIN PRIETO, JOSE MARIA MORENO-PLANAS, ALVARO GIRALDEZ, J MIGUEL MORENO-SANFIEL, NEIL KAPLOWITZ, M ISABEL LUCENA, RAÚL J ANDRADE.

Comprehensive analysis and further insights gained from the long-term experience of the Spanish DILI Registry.

Journal of Hepatology 2021. 10.1016/j.jhep.2021.01.029

IF 2019: 20.582 (D1: 2/88)

2. RIANNE A WEERSINK, ISMAEL ALVAREZ-ALVAREZ, INMACULADA MEDINA-CÁLIZ, JUDITH SANABRIA-CABRERA, MERCEDES ROBLES-DÍAZ, AIDA ORTEGA-ALONSO, MIREN GARCÍA-CORTÉS, ELVIRA BONILLA, HAO NIU, GERMAN SORIANO, MIGUEL JIMENEZ-PEREZ, HACIBE HALLAL, SONIA BLANCO, NEIL KAPLOWITZ, M ISABEL LUCENA, RAÚL J ANDRADE  
Clinical Characteristics and Outcome of Drug-Induced Liver Injury in the Older Patients: From the Young-Old to the Oldest-Old

Clin Pharmacol Ther. 2021; 109(4):1147-1158.doi: 10.1002/cpt.2108.

IF 2019: 6.565 (D1:16/271)

3. HAO NIU, JUDITH SANABRIA-CABRERA, ISMAEL ALVAREZ-ALVAREZ, MERCEDES ROBLES-DIAZ, SIMONA STANKEVIIT, GURUPRASAD P AITHAL, EINAR S BJÖRNSSON, RAUL J ANDRADE, M ISABEL LUCENA

Review. Prevention and management of idiosyncratic drug-induced liver injury: Systematic review and meta-analysis of randomised clinical trials

Pharmacol Res. 2021; 164:105404. doi: 10.1016/j.phrs.2020.105404. PMID: 33359912

IF 2019: 5.893 (D1: 19/271) Senior Author

4. JIMÉNEZ-PÉREZ M, GONZÁLEZ-GRANDE R, GARCÍA-CORTÉS M, ANDRADE RJ.

Drug-induced liver injury after liver transplantation.

Liver Transpl. 2020; 26(9): 1167-1176. doi: 10.1002/lt.25804.

IF 2019: 4.570. (D1: 15/210). CORRESPONDING AUTHOR. Editorial acompañante.

5. MIREN GARCIA-CORTES, MERCEDES ROBLES-DIAZ, CAMILLA STEPHENS, AIDA ORTEGA-ALONSO, M. ISABEL LUCENA & RAÚL J. ANDRADE.

Review Article. Drug induced liver injury: an update

<https://link.springer.com/article/10.1007/s00204-020-02885-1>

Archives of Toxicology 2020; 94 (10): 3381-3407 CORRESPONDING AUTHOR.

<https://doi.org/10.1007/s00204-020-02885-1>

IF 2019: 5.059 (D1: 9/92).

6. M ISABEL LUCENA, JUDITH SANABRIA, MIREN GARCIA-CORTES, CAMILLA STEPHENS, RAUL J ANDRADE.

Review. Drug-Induced Liver Injury in the elderly.

Lancet Gastroenterology & Hepatology 2020; 5 (9): 862-874

[https://doi.org/10.1016/S2468-1253\(20\)30006-6](https://doi.org/10.1016/S2468-1253(20)30006-6)

IF 2019: 14.789 (D1: 5/88)

7. CLINICAL PRACTICE GUIDELINES PANEL: CHAIR: RAUL J. ANDRADE; PANEL MEMBERS: GURUPRASAD P. AITHAL, EINAR S. BJORNSSON, NEIL KAPLOWITZ, GERD A. KULLAK-UBLICK, DOMINIQUE LARREY; EASL GOVERNING BOARD REPRESENTATIVE: TOM H. KARLSEN.

EASL Clinical Practice Guidelines: Drug-induced liver injury

European Association for the Study of the Liver.

<https://doi.org/10.1016/j.jhep.2019.02.014>

Journal of Hepatology 2019; 70: 1222-1261

IF 2019: 20.582 (D1)

8. ANDRADE RJ, CHALASANI N, BJÖRNSSON ES, SUZUKI A, KULLAK-UBLICK GA, WATKINS PB, DEVARBHAVI H, MERZ M, LUCENA MI, KAPLOWITZ N, AITHAL GP.

Review. Drug-induced liver injury.

Nat Rev Dis Primers. 2019; 5(1):58. doi: 10.1038/s41572-019-0105-0.

IF 2019: 40.689 (D1). CORRESPONDING AUTHOR

9. MEDINA-CALIZ I., ROBLES-DIAZ M., GARCIA-MUNOZ B., STEPHENS C., ORTEGA-ALONSO A., GARCIA-CORTES M., GONZALEZ-JIMENEZ A., SANABRIA-CABRERA J.A., MORENO I., FERNANDEZ M.C., ROMERO-GOMEZ M., NAVARRO J.M., BARRIOCANAL A.M., MONTANE E., HALLAL H., BLANCO S., SORIANO G., ROMAN E.M., GOMEZ-DOMINGUEZ E., CASTIELLA A., ZAPATA E.M., JIMENEZ-PEREZ M., MORENO J.M., ALDEA-PERONA A., HERNANDEZ-GUERRA M., PRIETO M., ZOUBEK M.E., KAPLOWITZ N., LUCENA M.I., ANDRADE R.J.

Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury.

Journal of Hepatology 2016 ;65(3):532-42.

doi: 10.1016/j.jhep.2016.05.003.

IF 2019: 20.582 (D1).

Q1 SENIOR:

10. INMACULADA MEDINA-CALIZ, MIREN GARCIA-CORTES, ANDRES GONZALEZ-JIMENEZ, MARIA R. CABELLO, MERCEDES ROBLES-DIAZ, JUDITH SANABRIA-CABRERA, ROCIO SANJUAN-JIMENEZ, AIDA ORTEGA-ALONSO, BEATRIZ GARCÍA-MUÑOZ, INMACULADA MORENO, MIGUEL JIMENEZ-PEREZ, M CARMEN FERNANDEZ, PERE GINÉS, MARTIN PRIETO, ISABEL CONDE, HACIBE HALLAL, GERMAN SORIANO, EVA ROMAN, AGUSTIN CASTIELLA, ENCARNACION BLANCO-REINA, MARIA R. MONTES, MARTA QUIROS-CANO, FLORES MARTIN-REYES, M ISABEL LUCENA, RAUL J. ANDRADE, on behalf of the Spanish DILI Registry.

Herbal and dietary supplement-induced liver injury in the Spanish DILI Registry.

<https://doi.org/10.1016/j.cgh.2017.12.051>

Clinical Gastroenterology and Hepatology (CGH) 2018; 16: 1495-1502.

IF 2019: 8.549 (Q1)

11. ZOUBEK ME, GONZÁLEZ-JIMENEZ A, MEDINA-CÁLIZ I, ROBLES-DÍAZ M, HERNANDEZ N, ROMERO-GÓMEZ M, BESSONE F, HALLAL H, CUBERO FJ, LUCENA MI, STEPHENS C, ANDRADE RJ.

High Prevalence of Ibuprofen Drug-Induced Liver Injury in Spanish and Latin-American Registries.

Clin Gastroenterol Hepatol. 2018; 16 (2):292-294

doi: 10.1016/j.cgh.2017.07.037.

IF 2019: 8.549 (Q1)

#### Projects

RESEARCH SUPPORT:

International Competitive grants:

Novel Combo Assay for Early Detection of Drug Induced Liver Injury (DILI). Programme: Eurostars. Code: E!114589 LiverAce.

Entities:

1. DESTINA Genómica S.L. Spain. IPs: Dr Juan José Díaz Mochón & Dr Salvatore Pernagallo

2. Datamedrix GmbH Austria. IP: Mr Andreas Redl MsC  
3. AIT Austrian Institute of Technology GmbH Austria. IP: Dr Christa Nöhhammer  
4. Universidad de Málaga IBIMA Spain (subcontracted). IPs: Dra Maribel Lucena & Dr Raúl Andrade Bellido  
5. University of Edinburgh, Royal Infirmary of Edinburgh UK (subcontracted). IP: Dr. James Dear.  
Funding agency: Centro para el Desarrollo Tecnológico Industrial (CDTI) en España y FFG Österreichische Forschungsförderungsgesellschaft mbH en Austria.  
Budget: 1417892,00  
Year: 2021. Duration: 25 months

EASL Registry Research Grant Programme 2020  
Title: Checkpoint-inhibitor induced liver injury: The CHILI registry  
PI: Palak Trivedi. Collaborator: Raúl J. Andrade  
Funding Agency: European Association for the Study of the Liver (EASL)  
Years: 2020-2022. Budget: 63,665  
COST ACTION CA17112 - Prospective European Drug-Induced Liver Injury Network (PRO-EURO DILI NET)  
PI: Raúl J. Andrade. Co-IP: Guruprasal Aithal.  
Funding agency: European Union (H2020)  
Years: October 2018-October 2022. Budget: 102.000 / year

IMI2- Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease.  
International agreement UMA-SAS project H2020 JTI IMI TRANSBIOLINE 2019-2023  
PI: Raúl J. Andrade  
Funding agency: European Union. Years: 2019-2013. Budget: 188.947,00

EASL Registry Research Grants Programme. Title: Creation of a European Prospective Drug-Induced Liver Injury Registry (Pro-Euro-DILI Registry).  
Principal investigator: Raúl J. Andrade  
Researchers: University of Malaga (Spain): M<sup>a</sup> Isabel Lucena, Stephens, Mercedes Roblès-Díaz, Inmaculada Medina-Cáliz; University of Nottingham, UK: Guru Aithal.  
Collaborating centres: Landspítali University Hospital, Iceland: Einar Björnsson; University Hospital of Santa Maria, Portugal: Helena Cortez-Pinto; University of Dundee, Scotland/UK: John Dillon.  
Funding agency: European Association for the Study of the Liver (EASL)  
Budget: 50.000 - Years: 2014-2015

SAFE-T Safer and faster Evidence Based Translation. SAFE-T INTERFACE EUROPE. Grant Agreement number 523 705.  
Principal Investigator: Raúl J. Andrade  
Researchers: M<sup>a</sup> Isabel Lucena, Camilla Stephens  
Funding agency: INNOVATIVE. MEDICINES INITIATIVE. European Union.  
Budget: 149.400 Years: 2011-2014

Research line: Metabolic syndrome and Liver diseases  
Proyecto FLIP: Stop Fatty Liver Progression  
Partner n° 12 - RTD Spain  
PI: Manuel Romero-Gómez. Collaborators: Raúl J Andrade, Miren García Cortes, Inmaculada Moreno  
Years: 01/01/2009-31/12/2013  
Study title: "Oxidative Stress Mechanisms in Drug-Induced Liver Injury",. Collaborative work among Ibima-UMA Prof Christian Trautwein and Dr. Francisco Javier Cubero Department of Internal Medicine III: Gastroenterology, Metabolic Disorders and Intensive Care Unit; University Hospital and Medical Faculty of RWTH AACHEN University, Alemania. Doctoral thesis Miguel Zoubeck 2014.

Research proposal submitted in Sept 2014 to the FDA which includes the following collaborating centres:

1 Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, FDA.

2 Director, Division of Gastroenterology, Department of Medicine, Central Arkansas Veterans Healthcare System (CAVHS)

3 Division of Systems Biology, National Center for Toxicological Research, FDA.

4 Clinical Pharmacology Service. IBIMA, University of Malaga. Spain

5 Office of Pharmacovigilance and Epidemiology, CDER/FDA

6 Director, Office of Clinical Pharmacology, CDER/FDA

7 Director UGC Gastroenterology, IBIMA-HUM, University of Malaga, Malaga, Spain

8 Department of Information, University of Arkansas at Little Rock.

9 Director, Office of Computational Science, Office of Translational Science, CDER.

Project title: Unraveling drug-patient interaction in Drug-Induced Liver Injury by translating genomics discoveries into a population perspective to complement the bench-to-bedside model of translation.

Principal investigator: Yuping Wang

Total proposed budget \$298,000

Funding period: March, 01, 2015- Feb, 28, 2017.

Co-Investigators: Ayako Suzuki<sup>2</sup>, Joshua Kwekel<sup>3</sup>, Maribel Lucena<sup>4</sup>, John Senior<sup>5</sup>, Issam Zineh<sup>6</sup>, Raul J Andrade<sup>7</sup>, Michael Chung<sup>8</sup>, Gang Chen<sup>8</sup>, Lilliam A. Rosario<sup>9</sup>, Wen Zou<sup>1</sup>, James Fuscoe<sup>3</sup>, William Mattes<sup>3</sup>, James Chen<sup>1</sup>, Xiaowei Xu<sup>7</sup>, Weida Tong<sup>1</sup>

Collaboration with Liverpool University. Centre for Drug Safety Sciences. Prof Kevin Park. Characterization of biomarker profiles in patient samples with DILI.

Collaboracion with Neil Kaplowitz and his center.

NEIL KAPLOWITZ, M.D. Professor and Chief Division of Gastroenterology Keck School of Medicine of USC University of Southern California 2011 Zonal Ave, HMR101 Los Angeles, CA 90033

National Competitive grants:

Title: Evaluation of comedication and trajectories diseases in the modulation of drug-induced liver damage. Code PI18/01804

Main researcher: Raúl J. Andrade

Co-Investigators: Jessica Gasca Bellido, Inmaculada Medina Caliz, Aida Ortega Alonso, Judith Adriana Sanabria Cabrera, Fernando Moreno Jabato, Alejandro Jose Cueto Sanchez.

Funding agency: Carlos III Health Institute.

Budget: 58.987,50 . Years: 2019-2021

Title: Analysis of physico-chemical drug properties, host factors and their interaction in hepatotoxicity phenotype presentation and outcome. Code PI15/01440

Main researcher: Raúl J. Andrade

Co-Investigators: Mercedes Robles-Díaz, Juan Antonio García, Inmaculada Medina Cáliz, Andrés Gonzalez Jimenez, Aida Ortega Alonso, David Velazco Sanchez.

Funding agency: Carlos III Health Institute.

Budget: 70.180 . Years: 2016-2018

Title: Long Term study of patients with DILI to determine morbimortality and susceptibility to develop new DILI episodes. Code PI12/00620.

Principal Investigator: Raúl J. Andrade

Co-Investigators: CARMEN FERNANDEZ SANCHEZ, MIREN GARCIA CORTES, MERCEDES ROBLES DIAZ, BEATRIZ GARCIA MUÑOZ, INMACULADA MEDINA CALIZ, HACIBE HALLAL HACHEM, JOSE MARIA MORENO PLANAS.

Funding agency: Carlos III Health Institute. Budget: 35.500 , Years: 2013-2015

Title: Role of the genetic variability of drug-transporter genes ABCB4, ABCB11, ABCC2, ABCB1 AND SLCO1B1 in the susceptibility to develop drug-induced idiosyncratic liver injury and its clinical expression. Code FIS PS09/01384

Principal Investigator: Raúl J Andrade.

Collaborating: María Cabello, Eugenia Ulzurrun, Mercedes Robles-Diaz, Esperanza Crespo, Miren Garcia-Cortes.

Funding agency: Carlos III Health Institute.

Budget: 69.575 , years: 2010-2012

Independent (non-commercial) Clinical Research Title: A phase IV, multicenter, randomized, double-blind, placebo-controlled study to evaluate efficacy and safety of Sorafenib in patients with hepatocellular carcinoma after radiological progression. Code PROYECTO DE INVESTIGACIÓN CLINICA INDEPENDIENTE. EC11-185

Principal Investigator: José Luis Montero Álvarez

Collaborating: Raúl J Andrade.

Funding Agency: Ministry of Health

Budget: 188.315,00 ; years 2012-2014

Non-commercial clinical research projects with human medicines. Code: EC08/00116

Principal investigator: Dra. E. Ocete Hita (H. Clínico S Cecilio, Granada)

Researchers: The Drs Lucena, Andrade, Salmerón, Giménez (H.Torrecárdenas) , Flores (H. Puerta del Mar), Ibarra (H. Reina Sofía), Monteruel (H. De Cruces), Martínón (HCU de Santiago), Del Castillo (HGU Gregorio Marañón) y Romero (HUVN).

Funding agency: Carlos III Health Institute.

Budget: 31.460 . Years: (2009-2011)

Independent clinical research EC07/90910

RISK OF HEPATOTOXICITY ASSOCIATED WITH TREATMENT OF TUBERCULOSIS INFECTION. PHARMACOECONOMIC EVALUATION OF THE HEPATOTOXICITY

Principal investigator: M. Isabel Lucena

Co-Investigators: Ketevan Patchkoria, Manuel Carnero, José Luis Velazco, Raquel Cueto, Francisco Martos, Antonio García. Budget: 27.225 . Years: 2008-2009

Regional Competitive grants:

Integrated analysis of pharmacological properties, host factors, epigenetic profile and its interaction, on the clinical phenotype and severity of drug-induced liver injury.

PIs: Raúl J. Andrade; Mercedes Robles-Diaz

Co-Investigators: Laura Sanz Villanueva, Andrés González-Jimenez, Judith Sanabria Cabrera, Rocio Sanjuan Jimenez, Jessica Gasca-Bellido.

Proyectos I+D+I - Programa Operativo FEDER Andalucía 2014-2020

Code: UMA18-FEDERJA-193

Funding agency: Andalusian Health Service.

Years: November 2019- November 2021. Budget: 28.650

Exosomes, the immune response and its modulation by the GUT microbiota in the identification of mechanistic and prognostic hepatotoxicity biomarkers.

PIs: M<sup>a</sup> Isabel Lucena; Camilla Stephens.

Co-Investigators: M García Cortes, M Robles Díaz, A Alonso Ortega, J Sanabria Cabrera, M Jiménez, R Andrade.

Convocatoría PAIDI 2018. Ayudas a proyectos de I+D+I Programa Operativo FEDER 2014-2020.

Code: PY18-3364.

Funding agency: Andalusian Agency of Knowledge.

Years: 2020-2023 (36 months). Budget: 140.352

ANDALUSIAN NETWORK FOR THE STUDY OF THE LIVER DISEASES. AC-0073-2013.

Principal investigator: Raúl J. Andrade

Co-Investigators: M. Isabel Lucena, Manuel Romero Gómez, Francisco CAbello-Ruiz Osuna, Miguel Jimenez Pérez, Jose María Navarro Jarabo, Carmen Fernández Sánchez)

Funding agency: Ministry of Health, Social Policy and Equality.

Amount: 101.000 - Years: 2014-2015

Investigation of associations between MHC alleles and the susceptibility to develop drug-induced liver injury. P10-CTS 6470.

Principal investigator: M<sup>a</sup> Isabel Lucena;

Co-Investigators: Francisco Ruiz Cabello, Miguel Angel Lopez Nevot, Raúl J. Andrade, Camilla Stephens, Yolanda Borraz, Eugenia Ulzurrun

Funding agency: Regional research project, Andalusian Health Service, 2010.

Amount: 143.755,75 - Years: 2011-2014.

I+D agreements with public organisms

CB07/04/2008. GRUPO DE HEPATOPATÍAS ASOCIADAS A MEDICAMENTOS. CIBERehd (CENTRO DE INVESTIGACIÓN BIOMEDICA EN RED (Networked Biomedical Research Center) DE ENFERMEDADES HEPATICAS Y DIGESTIVAS (Hepatic and Digestive Diseases) )  
www.ciberehd.org

Principal investigator: RAUL ANDRADE. Researchers: M ISABEL LUCENA

Funding agency: CIBERehd (Network-based biomedical research Centre)

Years: 2017-2021. Amount: 50.000

Year: 2016- Amount: 42.000

Year: 2015- Amount: 50.000

Year: 2014- Amount: 42.000

Year: 2013- Amount: 52.000

Year: 2012- Amount: 61.183

Year: 2011- Amount: 80.000

Year: 2010- Amount: 70.000

Year: 2009- Amount: 65.000

Collaboration Agreement between the Spanish Medicine Agency and the University of Malaga, through the Pharmacology & Medicine department for the study of Drug-Induced Liver Injury.

Principal investigators: M<sup>a</sup> Isabel Lucena Gonzalez, Raúl J Andrade Bellido

Funding agency: The Spanish Medicine Agency

Amount: 27.000 . Year: 2007

Amount: 27.000 . Year: 2008

Amount: 25.636 . Year: 2009

Amount: 21.122 - Years: 2010-11

Amount: 21.122 . Years: 2011-12

Amount: 50.820 . Years: 2013- 2015

Amount: 50.820. Years: 2016-2017.

Amount: 60.500. Years: 2018-2020

Amount: 60.500.Years: 2020-2022

RESEARCH PLAN. University of Málaga (vicerrector of scientific research) grant for the setting-up of a clinical trial network in DILI.

PI: M<sup>a</sup> Isabel Lucena. Co-Investigators: Raúl J. Andrade, María Cabello Porras, Inmaculada Bellido, Encarnación Blanco Reina, Javier Pérez-Frias, Ismael Álvarez-Álvarez, Judith Sanabria-Cabrera, Mercedes Roblés-Díaz, Hao Niu, Miren García-Cortés, Aida Ortega-Alonso, Guruprasad Aithal, Anna Licata, Einar Stefán Björnsson, Gerd A. Kullak-Ublick.

Code: 2020/REGSED-8324

Year: 25/06/2020 25/06/2021. Budget: 4000

RESEARCH PLAN. University of Málaga (vicerrector of scientific research) grant for the organization of the I Working groups meeting of the COST in the University of Malaga.

Main researcher: M<sup>a</sup> Isabel Lucena. Co-investigator: Raúl J. Andrade.

Funding agency: University of Málaga.

Year: 2019. Amount: 4.000

RESEARCH PLAN. University of Málaga (vicerrector of scientific research) grant for the setting-up of the Transbioline Registry

Principal investigator: M. Isabel Lucena. Co-IP: Raúl J. Andrade

Budget: 4.000 Year: 2018-2019

RESEARCH PLAN. University of Málaga (vicerrector of scientific research) grant for the organization of the 2nd Meeting CIOMS in Málaga. 14-15 November 2017.

Amount: 4.000 Year: 2017

RESEARCH PLAN. University of Málaga (vicerrector of scientific research) grant for the setting-up of thematic networks: Prospective European Drug-Induced Liver Injury Registry (Pro-Euro DILI registry)

Principal investigators: M. Isabel Lucena & Raúl J. Andrade.

Budget: 4.000 Year: 2015

RESEARCH PLAN. University of Málaga (vicerrector of scientific research) grant for the setting-up of thematic networks: Regional network for the identification and characterization of hepatotoxicities.

Principal investigators: M. Isabel Lucena & Raúl J. Andrade.

Funding agency: University of Málaga.

Budget: 4.000 Year: 2014.

RESEARCH PLAN. University of Málaga (vicerrector of scientific research) grant for the setting-up of thematic networks: Drug-Induced Liver Injury.

Principal investigator: M. Isabel Lucena & Raúl J. Andrade.

Funding agency: University of Málaga. Budget: 4.000 Year: 2013

AUIP grant (Iberoamerican Postgraduate University Association, AUIP) for the setting-up of an Ibero-American hepatotoxicity network. SLADILIN study Project as a research member of the AUIP.

Year: 2013- Amount: 1.500

RESEARCH PLAN. University of Málaga (vicerrector of scientific research) grant for the setting-up of thematic networks: Regional network for the identification and characterization of hepatotoxicities.

Principal investigator: M. Isabel Lucena & Raúl J. Andrade.

Funding agency: University of Málaga.

Amount: 4.000 Year: 2014.

RESEARCH PLAN. University of Málaga (vicerrector of scientific research) grant for the setting-up of thematic networks: Drug-Induced Liver Injury.

Principal investigator: M. Isabel Lucena & Raúl J. Andrade.

Funding agency: University of Málaga.

Amount: 4.000 Year: 2013

PAIDI (Plan Andaluz de Investigación). Research group: The Lipids and Atherosclerosis research unit (General pathology)". CTS-159

Principal investigator: Pedro González Santos



Co-investigators: Raúl J. Andrade,  
Funding agency: Economics, Innovation and Science regional Ministry.  
Years: 1994-up to date

#### PRIVATE CONTRACTS, SCIENTIFIC SOCIETIES

Collaboration agreement between NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST, University of Nottingham, FIMABIS, IBIMA&PFIZER. Transfer of the Data and Material from "Pro-Euro-DILI Registry" and "NASH" to Pfizer.

Project: Assessment of novel DILI biomarkers in retrospective Pro Euro DILI cohort  
Code: AC00031. PIs: Raúl J. Andrade; Guru Aithal. Co-Investigators: MI Lucena  
Budget: 19.415,31 . Years: 07.05.2020-31.12.2020

Research Project Agreement between PREGLEM S.A & RAÚL J. ANDRADE (University of Málaga) entitled: Ulipristal: analysis of the potential associated risk of liver injury. Project nº: 8.06/5.34.5133. Budget: 46900. Years: 2018. Project nº: 806/34.5288. Years: 2019-2021. Budget: 80.000

Research Project Agreement between Schwabe GmbH and Co. KG & RAÚL J. ANDRADE (University of Málaga) entitled: Liver injury by herbal dietary supplements or medicinal products. Project Nº: 701079.01.409. Budget: 46.550. Years: 2019

#### GILEAD SCIENCES EUROPE LTD MASTER SERVICES AGREEMENT

Collaboration with Gilead Science Europe on the co-morbidities and concomitant medication usage in Chronic Hepatitis C. Year: 2015

Collaboration Agreement between the Spanish Foundation for Functional Gastrointestinal Disorders (FEAD), the University of Malaga and D<sup>a</sup> María Isabel Lucena González and D<sup>a</sup> Mercedes Robles-Díaz for a research. Project: Support of a multicenter and multidisciplinary network of hepatotoxicity induced with some herbal products in Ibero-America.

Researchers: Mercedes ROBLES DIAZ; M<sup>a</sup> Isabel Lucena; Raúl J. Andrade Bellido; Andrés González; Inmaculada Medina; Ana F. González; Fernando Bessone; Nelia Hernández; Milagros Dávalos; Marco Arrese; Nahum Méndez; Raymundo Paraná  
Amount: 6.000 -Years: 2014

#### COLLABORATION AGREEMENT BETWEEN BIOIBERICA S.A. AND THE UNIVERSITY OF MÁLAGA THROUGH THE PHARMACOLOGY AND MEDICINE DEPARTMENT.

Principal investigators: M<sup>a</sup> Isabel Lucena Gonzalez, Raúl J Andrade Bellido  
Funding agency: BIOIBERICA S.A  
Years: May 2013 May 2016

#### INTERNATIONAL SAE CONSORTIUM LTD.

International Consortium on Drug Hypersensitivity (IDILIC) (Network)  
Genome wide analysis and sequencing on drugs-induced liver injury  
Principal investigators: M I Lucena, R J Andrade, C Stephens  
Years: 2010-2012 Amount: 227.000

#### NATIONAL RESEARCH NETWORKS:

Principal Investigator of the CIBERehd (Networked Biomedical Research Center) (<http://www.ciberisciii.es>)

IBIMA (Malaga Institute of Biomedical Research) ([www.ibima.eu](http://www.ibima.eu))

Member of the scientific committee of the Andalusian Society of Gastroenterology ([www.sapd.es](http://www.sapd.es))

Expert of the Spanish Medicines Agency in the Evaluation of liver safety of drugs (<http://www.aemps.gob.es>)

Member of the scientific committee of the Spanish Society for the Study of the Liver ([www.aeeh.es](http://www.aeeh.es))

Member of the scientific committee of the Spanish Society of Gastroenterology ([www.sepd.es](http://www.sepd.es))

#### Memberships

##### NATIONAL RESEARCH NETWORKS:

Principal Investigator of the CIBERehd (Networked Biomedical Research Center) (<http://www.ciberisciii.es>)

IBIMA (Malaga Institute of Biomedical Research) ([www.ibima.eu](http://www.ibima.eu))

Member of the scientific committee of the Andalusian Society of Gastroenterology ([www.sapd.es](http://www.sapd.es))

Expert of the Spanish Medicines Agency in the Evaluation of liver safety of drugs (<http://www.aemps.gob.es>)

Member of the scientific committee of the Spanish Society for the Study of the Liver ([www.aeeh.es](http://www.aeeh.es))

Member of the scientific committee of the Spanish Society of Gastroenterology ([www.sepd.es](http://www.sepd.es))

##### MEMBERSHIP IN INTERNATIONAL PROFESSIONAL ORGANIZATIONS:

European Association for the Study of Liver Diseases

American Association for the Study of the Liver (AASLD)

Member of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) of the European Medicines Agency (EMA)

Member of the European Clinical Research Infrastructures Network (ECRIN).

International Serious Adverse Event Consortium.

International Consortium on Drug Hypersensitivity (IDILIC) (Network)

SAFE-T Consortium (Safer and Faster Evidence-based Translation) of the European Unions

Innovative Medicines Initiative (<http://www.imi-safe-t.eu>)

##### EDITORIAL ASSIGNMENTS:

Editorial Board of Current Drug Safety, World Journal of Gastroenterology, International Journal of Clinical Pharmacology and Therapeutics, Hepatology, Gastroenterology and Hepatology

External referee of : Gastroenterology, Hepatology, Journal of Hepatology, Alimentary Pharmacology & Therapeutics, Lancet, Drug Safety, Clinical Infectious Diseases among others high rated journals, The Lancet, Hepatology

Associate editor of Liver International (2014)

Full member of the following societies: Sociedad Andaluza de Patología Digestiva, Sociedad Española de Patología Digestiva, Asociación Española para el Estudio del Hígado, European Association for the Study of the Liver, American Association for the Study of Liver Disease

Member of the International Serious Adverse Event Consortium (ISAEC)

Member of the steering committee of the Standardization Phenotype Project of the ISAEC

Leader investigator of the Spanish Drug Induced Liver Injury (DILI) Registry a network intended to capture cases of hepatotoxicity and to perform phenotypic and genetic studies in the subject.

Member of the steering committee of the Group of Special Interest in Hepatotoxicity patronised by the American Association for the Study of Liver Diseases.

Speaker and moderator in several regional as well as national and international meetings and symposia.

Member of the editorial board of:

-Current Drug Safety.

-World Journal of Gastroenterology.

-International Journal of Clinical Pharmacology and Therapeutics.

-Hepatology

-Gastroenterology and Hepatology

External referee of : Gastroenterology, Hepatology, Journal of Hepatology, Alimentary Pharmacology & Therapeutics, Lancet, Drug Safety, Clinical Infectious Diseases among others high rated journals, The Lancet, Hepatology

Member of the working team on the Cholestatic and Drug-induced Liver Disease section of the

EASL HEPAMAP project.

Guest of Honour of the Medical Sciences Faculty National University of Rosario, Argentine.

Part of the Reviewing board for the EASL International Liver Congress

CATEGORY: Alcoholic liver disease and Drug induced liver disease.

Our Group is part of the steering committee of important international initiatives in Hepatotoxicity: Phenotyping Standardisation Project in Hepatotoxicity and Hepatotoxicity Special Interest Group (SIG) of the American Association for the Study of Liver Diseases (AASLD).

#### Other Relevant Information

Raúl J. Andrade is Professor of Medicine and Director of the Department of Medicine at the University of Malaga. Director of the Unidad de Gestión Clínica de Ap Digestivo, University Hospital of Málaga. Founder and director of the Spanish Drug Induced Liver Injury (DILI) Registry ([www.spanishdili.uma.es](http://www.spanishdili.uma.es))-the first network specialized in the study of Drug Induced Liver Injury- and of the Spanish Latin-American DILI Network and the recently set-up Prospective European DILI Registry awarded by the European Association for the Study of the Liver (EASL). Appointed by the EASL as Chairman of the Clinical Practice Guidelines Council responsible for writing a new CPG on Drug Induced Liver Injury 2016. Chair of CIOMS (Council for International Organizations of Medical Sciences) working group on DILI 2017. Chair COST ACTION CA17112. Principal investigator of CIBERehd group. He leads the PAIDI CTS-1032 group, IP of IBIMA Group on Translational Clinical Pharmacology Expert of the European Medicines Agency (EMA) and the Spanish Medicines Agency in the Evaluation of liver safety of drugs. Member of the steering committee of the Standardization Phenotype Project of the International Serious Adverse Event Consortium and the steering committee of the Group of Special Interest in Hepatotoxicity (AASLD). Member of the working team on the Cholestatic and Drug-induced Liver Disease section of the EASL- HEPAMAP project. He is member of the expert panel of the EFSA (European Food Safety Authority) since 2016. Member of the Reviewing board for the EASL International Liver Congress (2013-2016). We are partner of the H2020 JTI IMI TRANSBIOLINE project, and the COST grant proposal Prospective European Drug-Induced Liver Injury Network. Invited speaker in international meetings such as: Gordon Research Conference, Maine, USA (2008); NIH Workshop: Drug-Induced Injury: Standardization of nomenclature and causality assessment (Maryland, USA 2008); EASL Postgraduate course Cholestatic disease of the liver and bile ducts, (Berlin, Alemania 2011); EASL IASL JOINT SYMPOSIUM: Drug Induced Liver Disease: Global perspective, (London 2014); Co-Chair Meet-The Professor Lunch at the AASLD(Boston, USA 2014); SYMPOSIUM OF THE IUPHAR-CD - EACPT: "Clinical Networks and Consortia in Drug-Induced Liver Injury (DILI): an opportunity for advancing Safety Sciences" (Madrid, 2015); EASL/AASLD Monothematic Conference on Autoimmune Hepatitis (London, 2015); Japan Digestive Disease Week (Tokyo, 2015); 5th Symposium Hepatology 2015 on Drug-Induced Liver Injury (Switzerland, 2015); EASL Monothematic Conference on NASH (Riga, Latvia 2016); the AASLD Liver Meeting (Boston, USA, 2016). The 26th Conference of the APASL (Shanghai 2017); International Conference on Fatty Liver (Sevilla, Spain 2017); EASL Monothematic Conference Cholangiocytes in health and Disease: from basic Science to novel treatments (Oslo, Norway 2017). He is Associate editor of Liver International (Q1) and member of the editorial board of: Hepatology (2012-2016) (D1) and Frontiers in Pharmacology (Q1), He published over 250 articles in peer-review journals, and 43 book chapters. He has an h-index of 48 and 9606 total citations by 6219 documents. 23 publications were cited more than 100 times and 40 original articles received more than 50 citations. He presented more than 340 communications in International & National Scientific Meetings. In the past 5 years, he has directed 10 PhD thesis included 2 international thesis.

Guest of Honour of the Medical Sciences Faculty National University of Rosario, Argentine.

Expert for the SAG CVS meeting on Kynamro. EMA meeting, London, 10 Septiembre, 2012.

Participant of the European Scientific Board Meeting of Aegerion Pharmaceuticals. European Liver Safety Scientific Advisory Meeting- Amsterdam, 13 September, 2012.

Expert commentator in the exposition of the oral Works

Module: Hígado, hepatitis tóxica, viral y autoinmune durante la Semana Nacional de Gastroenterología. Organizer: The Mexican Association of Gastroenterology. Mérida, Yucatán. México. 17-21 November, 2012

Participation in the Hepamap EASL Roadmap to Hepatology Research in Europe.

Cholestatic and drug-induced liver disease.

Since 2012. Expert of the European Medicines Agency (EMA) in the Evaluation of liver safety of drugs.

2013. Member of the European Board of Gastroenterology and of the European Board of Hepatology.

2013. Member of the Reviewing board for the EASL International Liver Congress.

CATEGORY: Alcoholic liver disease and Drug induced liver disease.

2014. Special Section Editor in DILI in Liver International.